3. Administrative Core Dr. Samuel E. Adunyah and Dr. Steven Wolff, in conjuncfion with the other Partnership Co-Principal Invesfigators, will be responsible for the overall conduct of Partnership acfivities as well as the decision-making processes. These include: 1) oversight of the Partnership's objecfives to strengthen and expand competitive cancer research capabilifies 2) create stable, long-term collaborafive relationships between MMC, TSU and the VICC in cancer research, outreach, training and career development 3) promote a stable, long-term partnership based on mutually beneficial research excellence 4) overall planning, coordination and implementafion of internal and external evaluation activities 5) facilitafion of inter-insfitutional initiafives in cancer research 6) budgetary decisions. The MMC component of the Partnership will be administered and managed through well-established infrastructure under the leadership of the Lead Principal Invesfigator, Dr. Samuel E. Adunyah and Co-Principal Investigator, Dr. Steven Wolff. The administrative core is responsible for providing the support necessary to achieve and maintain the highest standards of excellence in cancer research at MMC. Since inception of the cancer partnership MMC has strengthened its cancer research infrastructure. This expansion of cancer research capability in MMC has gained the support of Departmental Chairs and Deans of the Schools of Medicine and Graduate Studies and Research to which some Partnership invesfigators will be reporting. As part if the overall partnership administrative core, our Administrative Core Leadership will play a key role in determining the overall direction for cancer research activities and cancer research training which meet goals and objectives ofthis Partnership. .

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA163069-04
Application #
8730567
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
4
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Meharry Medical College
Department
Type
DUNS #
City
Nashville
State
TN
Country
United States
Zip Code
37208
Umeukeje, Ebele M; Wild, Marcus G; Maripuri, Saugar et al. (2018) Black Americans' Perspectives of Barriers and Facilitators of Community Screening for Kidney Disease. Clin J Am Soc Nephrol 13:551-559
Vercruysse, Koen; Clark, Astiney; Alatas, Noor et al. (2018) Polysaccharide-mediated synthesis of melanins from serotonin and other 5-hydroxy indoles. Future Sci OA 4:FSO280
Hull, P C; Buchowski, M; Canedo, J R et al. (2018) Childhood obesity prevention cluster randomized trial for Hispanic families: outcomes of the healthy families study. Pediatr Obes 13:686-696
Sanderson, Maureen; Aldrich, Melinda C; Levine, Robert S et al. (2018) Neighbourhood deprivation and lung cancer risk: a nested case-control study in the USA. BMJ Open 8:e021059
Ochieng, Josiah; Nangami, Gladys; Sakwe, Amos et al. (2018) Impact of Fetuin-A (AHSG) on Tumor Progression and Type 2 Diabetes. Int J Mol Sci 19:
Tantawy, Mohammed N; Charles Manning, H; Peterson, Todd E et al. (2018) Translocator Protein PET Imaging in a Preclinical Prostate Cancer Model. Mol Imaging Biol 20:200-204
Burroughs, Andrea Flores; Eluhu, Sylvia; Whalen, Diva et al. (2018) PML-Nuclear Bodies Regulate the Stability of the Fusion Protein Dendra2-Nrf2 in the Nucleus. Cell Physiol Biochem 47:800-816
Ignacio, Rosa Mistica C; Lee, Eun-Sook; Wilson, Andrew J et al. (2018) Chemokine Network and Overall Survival in TP53 Wild-Type and Mutant Ovarian Cancer. Immune Netw 18:e29
Wilkins, Consuelo H (2018) Putting The Person In Personalized Medicine Personalized Medicine: Empowered Patients In The 21st Century? By Barbara Prainsack New York (NY) : NYU Press , 2017 288 pp., $30. Health Aff (Millwood) 37:823-824
Ignacio, Rosa Mistica C; Dong, Yuan-Lin; Kabir, Syeda M et al. (2018) CXCR2 is a negative regulator of p21 in p53-dependent and independent manner via Akt-mediated Mdm2 in ovarian cancer. Oncotarget 9:9751-9765

Showing the most recent 10 out of 178 publications